Flavoxate
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Flavoxate: From Urinary Urgency/Frequency to Neurogenic Bladder
One-Sentence Summary
Flavoxate is a direct-acting (musculotropic) urinary tract antispasmodic historically used to relieve dysuria, urgency, frequency, and nocturia associated with lower urinary tract irritation. The TxGNN model screened 8 candidate indications; among these, Neurogenic Bladder shows the strongest mechanistic overlap with flavoxate’s known pharmacology (detrusor smooth-muscle relaxation), but currently 0 clinical trials and 0 publications support this specific indication in this evidence pack. The model’s single highest-scoring hit (ADHD, inattentive type) was independently flagged by the analysis itself as likely model noise with no plausible mechanism, and is not carried forward as the primary candidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (drug not marketed in Taiwan; no TFDA license record available) |
| Predicted New Indication | Neurogenic Bladder (obsolete term, per source ontology) |
| TxGNN Prediction Score | 99.13% |
| Evidence Level | L5 (model prediction only — no clinical trials or literature identified) |
| Taiwan Market Status (TFDA) | 未上市 (Not Marketed) |
| Number of TFDA Licenses | 0 |
| Recommended Decision | Hold |
Note on candidate selection: This Evidence Pack (
TW-DB01148-multi) contains 8 TxGNN-predicted indications for flavoxate, all rated L5 with zero supporting trials or literature. The top-ranked hit by raw score (ADHD, inattentive type, 99.75%) was assessed in the source rationale as a probable knowledge-graph artifact — flavoxate has no known central dopaminergic/noradrenergic activity, so no biologically plausible link exists. We report Neurogenic Bladder (rank 6, decision stage S1) as the lead candidate instead, since it aligns with flavoxate’s documented peripheral pharmacology. See the table below for all 8 candidates.
Other Candidate Indications Screened
| Rank | Disease | TxGNN Score | Evidence Level | Recommendation | Note |
|---|---|---|---|---|---|
| 1 | ADHD, inattentive type | 99.75% | L5 | Hold | Likely model noise — no CNS mechanism |
| 2 | Irritable Bowel Syndrome | 99.74% | L5 | Research Question | Plausible smooth-muscle class analogy (vs. mebeverine/alverine); unverified |
| 3 | Specific Developmental Disorder | 99.56% | L5 | Hold | Non-specific disease term, no mechanistic link |
| 4 | ADHD (general) | 99.39% | L5 | Hold | Same issue as rank 1 |
| 5 | Cauda Equina Syndrome | 99.27% | L5 | Hold | Surgical emergency; symptomatic overlap only |
| 6 | Neurogenic Bladder (obsolete) | 99.13% | L5 | Research Question | Strongest mechanistic fit — lead candidate |
| 7 | Gastroduodenitis | 99.12% | L5 | Hold | Symptomatic overlap only, no disease-modifying link |
| 8 | Peptic Ulcer Disease | 99.10% | L5 | Hold | Outdated anticholinergic-adjuvant rationale |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (DrugBank was queried successfully but the specific MOA field was not returned; see Data Gap DG002). Based on generally known pharmacology, flavoxate is a musculotropic (direct-acting) spasmolytic with weak anticholinergic and local anesthetic-like activity, acting directly on urinary tract smooth muscle — most notably the bladder detrusor — to relieve spasm-related irritative voiding symptoms such as urgency, frequency, dysuria, and nocturia.
Because this established pharmacology centers specifically on detrusor smooth-muscle relaxation, the model’s prediction of Neurogenic Bladder is mechanistically coherent: this condition is characterized by dysregulated detrusor activity (overactivity, non-compliance, or dyssynergia) causing urgency, frequency, and incontinence — the same symptom domain flavoxate is already used to manage. In contrast, the model’s absolute top-ranked candidates (ADHD subtypes, developmental disorders) require a central-nervous-system mechanism that flavoxate does not possess, and are best interpreted as embedding-level noise rather than genuine repurposing signals.
No clinical trial or literature evidence for flavoxate specifically in neurogenic bladder was found in this data cutoff. This absence likely reflects a data/indexing gap rather than mechanistic implausibility — flavoxate’s peripheral antispasmodic use already overlaps heavily with symptoms seen in neurogenic bladder, making a targeted literature search a reasonable next step rather than a dead end.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Flavoxate has 0 TFDA licenses on record and is currently not marketed in Taiwan (market_status: 未上市). No product name, dosage form, or approved indication text is available to summarize.
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA label warnings/contraindications retrieval is flagged as a Blocking data gap (DG001) in this evidence pack — this must be resolved before any Stage 1 (S1) safety screening can proceed. A drug-drug interaction (DDI) database query also returned no results (
not_found).
Conclusion and Next Steps
Decision: Hold
Rationale:
- All 8 candidate indications are rated L5 (model prediction only), with zero supporting clinical trials or literature across the board, and flavoxate is not currently marketed in Taiwan. A Blocking-severity data gap (TFDA label/warnings, DG001) means the drug cannot yet pass initial safety screening (S1), so no candidate — including the mechanistically favored Neurogenic Bladder — can advance beyond a research question at this time.
To proceed, the following is needed:
- Retrieve TFDA label warnings/contraindications (DG001 — Blocking; required before any S1 safety screening)
- Retrieve full DrugBank MOA text via API to confirm mechanistic detail (DG002 — High)
- Targeted literature/clinical-trial search using alternate terminology (e.g., “neurogenic detrusor overactivity,” “overactive bladder, neurogenic”) since the exact TxGNN disease label may not match how existing studies are indexed
- Drug-drug interaction (DDI) data source re-query, as the current lookup returned no results
- Confirmation of flavoxate’s original approved indication(s), which are not populated in this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.